ArticleVaccines2017
Virus-Like Particle (VLP) Plus Microcrystalline Tyrosine (MCT) Adjuvants Enhance Vaccine Efficacy Improving T and B Cell Immunogenicity and Protection against Plasmodium berghei/vivax.
Article in Vaccines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- Proteome-wide characterization of Plasmodium vivax antigens using a high-density peptide array.PLoS pathogens · 2026Article
- A VLPs based vaccine protects against Zika virus infection and prevents cerebral and testicular damage.NPJ vaccines · 2025Article
- Probing novel epitopes on the Plasmodium falciparum circumsporozoite protein for vaccine development.NPJ vaccines · 2024Article
- A self-adjuvanted VLPs-based Covid-19 vaccine proven versatile, safe, and highly protective.Scientific reports · 2024Article
- Novel adjuvants in allergen-specific immunotherapy: where do we stand?Frontiers in immunology · 2024Review
- Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines.International journal of biological macromolecules · 2023Review
- Review
- Review
- Advancements in protein nanoparticle vaccine platforms to combat infectious disease.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate.Vaccines · 2021Article
- Protective Immunity Induced by Virus-Like Particle Containing Merozoite Surface Protein 9 ofVaccines · 2020Article
- Vaccination Against Amyloidogenic Aggregates in Pancreatic Islets Prevents Development of Type 2 Diabetes Mellitus.Vaccines · 2020Article
- Review
- Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCTFrontiers in immunology · 2020Review
- Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing.The World Allergy Organization journal · 2019Article
- Article
- Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.Journal for immunotherapy of cancer · 2019Article
- DOPS Adjuvant Confers Enhanced Protection against Malaria for VLP-TRAP Based Vaccines.Diseases (Basel, Switzerland) · 2018Article
- Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases.Allergo journal international · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
Vaccination is the most effective prophylactic tool against infectious diseases. Despite continued efforts to control malaria, the disease still generally represents a significant unmet medical need. Microcrystalline tyrosine (MCT) is a well described depot used in licensed allergy immunotherapy products and in clinical development. However, its proof of concept in prophylactic vaccines has only recently been explored. MCT has never been used in combination with virus-like particles (VLPs), which are considered to be one of the most potent inducers of cellular and humoral immune responses in mice and humans. In the current study we assessed the potential of MCT to serve as an adjuvant in the development of a vaccine against malaria either alone or combined with VLP using
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.